Stadol NS (Butorphanol Tartrate) is sold by the Bristol-Myers Squibb Canada Inc. It is a narcotic analgesic in the form of a nasal spray that was introduced into the Canadian market in October of 1994.
The action is based on the allegation that the drug was marketed for migraine headache pain relief when the defendants knew or ought to have known that the users could easily become addicted.
A settlement has been reached with the defendants that resolves the litigation. The deadline to file a claim under the settlement was January 31, 2005. This settlement has concluded and all claims have been paid.
For further information please complete the contact form below.